An announcement from Lipocine ( ($LPCN) ) is now available. On November 4, 2025, Lipocine Inc. presented clinical data for LPCN 2401 at the ...

An announcement from IVD Medical Holding Limited ( ($HK:1931) ) is now available. IVD Medical Holding Limited has announced an extraordinary ...

Investors are watching for private updates on the job market as the government shutdown is days away from becoming the ...

Food and Drug Administration no longer agreed that clinical data for the Dutch company's gene therapy for Huntington's disease may be adequate for a marketing application, triggering a 57% slump in ...

Philips reports better-than-expected third-quarter profits, driven by AI tool launches and effective tariff mitigation ...

UniQure shares soared on positive AMT-130 Huntington's disease data, but plunged after the FDA reversed its stance on ...

The company expects to share safety and efficacy results from the RAMP-205 expansion cohort in first-line advanced pancreatic cancer and initial results from the Phase I/IIa trial evaluating VS-7375 ...

The COLA boost is slightly better than earlier estimates, even if we're not talking about a lot of money. But many retirees are struggling.

US stocks finished the first trading day of November mixed, with Big Tech names like Amazon (AMZN) and Nvidia (NVDA) rising ...

Meet some of the team behind UConn Health's effort to improve health care quality, address patient disparities with more REL ...

2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...

A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.